NASDAQ:SNSS - Sunesis Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $12.00
  • Forecasted Upside:
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
+0.30 (1.20%)
Get New Sunesis Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SNSS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SNSS

Analyst Price Target is $12.00
▲ +∞ Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Sunesis Pharmaceuticals in the last 3 months. The average price target is $12.00, with a high forecast of $12.00 and a low forecast of $12.00. The average price target represents a ∞ upside from the last price of $0.00.

This chart shows the closing price for SNSS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 contributing investment analysts is to buy stock in Sunesis Pharmaceuticals. This rating has held steady since February 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/23/2021OppenheimerUpgradeMarket Perform ➝ Outperform$12.00High
8/12/2020OppenheimerReiterated RatingHoldMedium
6/23/2020OppenheimerDowngradeOutperform ➝ Market PerformHigh
5/8/2020HC WainwrightLower Price TargetNeutral$10.00 ➝ $5.00Low
3/11/2020HC WainwrightBoost Price TargetNeutral$5.00 ➝ $10.00High
3/11/2020Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$30.00 ➝ $10.00High
3/10/2020CowenReiterated RatingHoldHigh
12/5/2019CowenReiterated RatingHoldHigh
11/13/2019HC WainwrightReiterated RatingNeutral ➝ HoldHigh
8/9/2019HC WainwrightReiterated RatingHold$15.00High
6/17/2019HC WainwrightReiterated RatingHold$20.00High
6/16/2019CowenReiterated RatingHoldMedium
3/12/2019HC WainwrightReiterated RatingHold$5.00Low
3/8/2019OppenheimerSet Price TargetBuy$60.00Low
12/20/2018HC WainwrightInitiated CoverageNeutral ➝ Neutral$5.00High
5/8/2018CowenReiterated RatingHoldHigh
3/8/2018Cantor FitzgeraldReiterated RatingHold$40.00High
12/14/2017OppenheimerInitiated CoverageBuy$70.00Low
12/11/2017Cantor FitzgeraldSet Price TargetHold$30.00High
12/11/2017Wells Fargo & CompanyUpgradeMarket Perform ➝ Outperform$28.60 ➝ $24.80High
12/5/2017Cantor FitzgeraldSet Price TargetHold$30.00High
12/5/2017Wells Fargo & CompanyDowngradeOutperform ➝ Market Perform$27.00 ➝ $20.00High
11/21/2017OppenheimerInitiated CoverageOutperform$70.00N/A
11/20/2017UBS GroupInitiated CoverageOutperformN/A
11/2/2017CowenReiterated RatingHoldN/A
9/27/2017Cantor FitzgeraldReiterated RatingHold$30.00Low
7/27/2017Cantor FitzgeraldReiterated RatingHold$30.00Low
5/2/2017Cantor FitzgeraldReiterated RatingHold$30.00High
12/28/2016Cantor FitzgeraldDowngradeBuy ➝ HoldN/A
11/3/2016CowenReiterated RatingHoldN/A
9/12/2016Cantor FitzgeraldReiterated RatingBuyN/A
9/12/2016CowenReiterated RatingHoldN/A
7/29/2016CowenReiterated RatingMarket PerformN/A
7/29/2016Wells Fargo & CompanyUpgradeMarket Perform ➝ OutperformN/A
(Data available from 7/25/2016 forward)
Sunesis Pharmaceuticals logo
Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of targeted inhibitors for the treatment of hematologic and solid cancers. Its lead product candidate is vecabrutinib, a non-covalent inhibitor of Bruton's tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial for the treatment of chronic lymphocytic leukemia, mantle cell lymphoma, and other B-cell malignancies. The company is also developing SNS-510, which is in preclinical pharmacology studies for the treatment of solid tumor and hematologic malignancies; various other partnered programs, such as TAK-580, a pan-Raf inhibitor program that is in Phase 1 clinical trial for the treatment of pediatric low-grade glioma; and vosaroxin, an anti-cancer quinolone derivative that intercalates DNA and inhibits topoisomerase II. It has a collaboration agreement with Biogen Idec MA, Inc. to discover, develop, and commercialize small molecule BTK inhibitors; and license agreement with Takeda Pharmaceutical Company Limited to develop and commercialize preclinical inhibitors of PDK1. Sunesis Pharmaceuticals, Inc. was founded in 1998 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $3.53
Low: $2.38
High: $5.32

52 Week Range

Now: N/A


1,198,965 shs

Average Volume

4,330,995 shs

Market Capitalization

$96.26 million

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Sunesis Pharmaceuticals?

The following equities research analysts have issued research reports on Sunesis Pharmaceuticals in the last year: Oppenheimer Holdings Inc., and Zacks Investment Research.
View the latest analyst ratings for SNSS.

What is the current price target for Sunesis Pharmaceuticals?

1 Wall Street analysts have set twelve-month price targets for Sunesis Pharmaceuticals in the last year. Their average twelve-month price target is $12.00. Oppenheimer Holdings Inc. has the highest price target set, predicting SNSS will reach $12.00 in the next twelve months. Oppenheimer Holdings Inc. has the lowest price target set, forecasting a price of $12.00 for Sunesis Pharmaceuticals in the next year.
View the latest price targets for SNSS.

What is the current consensus analyst rating for Sunesis Pharmaceuticals?

Sunesis Pharmaceuticals currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SNSS will outperform the market and that investors should add to their positions of Sunesis Pharmaceuticals.
View the latest ratings for SNSS.

What other companies compete with Sunesis Pharmaceuticals?

How do I contact Sunesis Pharmaceuticals' investor relations team?

Sunesis Pharmaceuticals' physical mailing address is 395 OYSTER POINT BOULEVARD SUITE 400, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company's listed phone number is 650-266-3500 and its investor relations email address is [email protected] The official website for Sunesis Pharmaceuticals is